ANTH - 1.60 Pre-market no at 1.83/1.84 Anthera Reports Positive Results From Phase 3 Study of Sollpura to Treat Exocrine Pancreatic Insufficiency http://stockcharts.com/c-sc/sc?s=ANTH&p=D&b=5&g=0&i=t48712554609&r=1513002045323 http://stockcharts.com/c-sc/sc?s=ANTH&p=W&b=5&g=0&i=t09752135570&r=1513002030285